­

About admin

This author has not yet filled in any details.
So far admin has created 98 blog entries.

Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial

BATON ROUGE, La., March 22, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Announces Presentation at the 2018 AACR Annual Meeting

BATON ROUGE, La., March 20, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Appoints Robert Neal Holcomb to Board of Directors

BATON ROUGE, La., March 19, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer

BATON ROUGE, La., March 08, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas

BATON ROUGE, La., Feb. 28, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Provides Updates on Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

BATON ROUGE, La., Feb. 26, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas

BATON ROUGE, La., Feb. 05, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time

BATON ROUGE, La., January 10, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial

100% Overall Survival Rate in 14 Evaluable Patients at One-Year Follow-Up BATON ROUGE, La., Dec. 21, 2017 -- OncBioMune Pharmaceuticals, [...]

100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

BATON ROUGE, La., Dec. 05, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]